The rare combination of large early stage investments in its pancreatic cancer R&D program and its Phase II clinical trial performance strongly bolsters Nuvilex’s (OTCQB – NVLX) prospects for approval of its treatment for advanced inoperable pancreatic cancer.

Today we are initiating coverage of Multi-Corp International Inc. (OTCPK – MULI). There is the potential for some really good news on Tuesday so read carefully lest that point slip by you. Now, if the news is neutral or bad the shares would go south but we are betting it will be good, rather than neutral or bad. The bottom line is that we introduced you to NORX on Monday at $0.94 and it hit $2.06 earlier this week. This is another really unconventional junior E&P story that has long term potential if things go their way, in addition to the trading aspect alluded to above.

According to a recent study published in the Journal of Biology Chemistry, Epigallocatechin gallate (EGCG), the most abundant catechin found in green tea, has demonstrated the ability to serve as a treatment for Alzheimer’s disease.

As Nuvilex Inc. (QTCQB - NVLX - $0.14 - Spec Buy) management can attest, scientists and clinicians often approach drug development and treatment very differently.

While a great deal of attention has been focused on the treatment and prevention of major diseases such as malaria and other conditions using key green tea extracts such as Epigallocatechin gallate (EGCG)

On the heels of the latest Barron's cover story, marijuana use is a topic that will continue to gain fans and ultimately approval.

While the benefits of FIT OPEB to municipalities have taken center stage, the FIT plan for wealthy and uber-wealthy individuals could be a meaningful profit center for INSCOR

The Company is successful in developing a treatment or preventive vehicle for malaria, it could be a very profitable game-changer for the Company given its South Africa plantation and botanical-based therapeutic and go a long way toward cost-effectively eliminating one of the world’s most severe health issues.